Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.

Autor:	Kaplonek P; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Wang C; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA., Bartsch Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Gorman MJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Bowman K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Dayal D; Space Exploration Technologies Corp, USA., Martin P; Space Exploration Technologies Corp, USA., Nowak R; Massachusetts General Hospital, USA., Hsieh CL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.; Space Exploration Technologies Corp, USA.; Brigham Women's Hospital, USA.; Massachusetts General Hospital, USA.; Broad Institute, USA., Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Julg B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Nilles EJ; Brigham Women's Hospital, USA., Musk ER; Space Exploration Technologies Corp, USA., Menon AS; Space Exploration Technologies Corp, USA., Fischer ES; Massachusetts General Hospital, USA., McLellan JS; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.; Space Exploration Technologies Corp, USA.; Brigham Women's Hospital, USA.; Massachusetts General Hospital, USA.; Broad Institute, USA., Schmidt A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Goldberg MB; Massachusetts General Hospital, USA., Filbin M; Massachusetts General Hospital, USA., Hacohen N; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.; Broad Institute, USA., Lauffenburger DA; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA., Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2021 May 12. Date of Electronic Publication: 2021 May 12.
DOI:	10.1101/2021.05.11.443609
Abstrakt:	The introduction of vaccines has inspired new hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against COVID-19, thus we profiled the earliest humoral signatures in a large cohort of severe and asymptomatic COVID-19 individuals. While a SARS-CoV-2-specific immune response evolved rapidly in survivors of COVID-19, non-survivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibody evolution. Given the conservation of S2 across β-coronaviruses, we found the early development of SARS-CoV-2-specific immunity occurred in tandem with pre-existing common β-coronavirus OC43 humoral immunity in survivors, which was selectively also expanded in individuals that develop paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu